Search Results

• • 191 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Ipilimumab ups survival in metastatic melanoma phase III trial

  From:Oncology (Vol. 24, Issue 7) Peer-Reviewed

  June 2010184 words Brief article, Repor... 1410LIpilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4), given alone or in combination with vaccine, increased overall survival (OS) in patients with unresectable stage III/IV melanoma for...

• VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy.

  Authors:Xing Huang, Xiaozhen Zhang, Enliang Li, Gang Zhang, Xun Wang, Tianyu Tang, et al.From:Journal of Hematology & Oncology (Vol. 13, Issue 1) Peer-Reviewed

  June 29, 20205,585 words Article 1660LVISTA (V-domain immunoglobulin suppressor of T cell activation) is a well-established immune regulatory receptor. However, pre-clinical investigations indicated more complicated influences of VISTA on cancer immunity...

• Current Diagnosis and Management of Small-Cell Lung Cancer

  Authors:Shuhang Wang, Stefan Zimmermann, Kaushal Parikh, Aaron S. Mansfield, and Alex A. AdjeiFrom:Mayo Clinic Proceedings (Vol. 94, Issue 8) Peer-Reviewed

  Aug. 201911,025 words Article 1660LAbstract Small-cell lung cancer (SCLC) is an aggressive disease with distinct pathological, clinical, and molecular characteristics from non--small-cell lung cancer. SCLC has high metastatic potential, resulting in a...

• Expression of programmed death-ligand 1 in cutaneous squamous cell carcinoma arising in sun-exposed and nonsun-exposed skin.

  Authors:Hiroyuki Goto, Kazunari Sugita, and Osamu YamamotoFrom:Indian Journal of Dermatology (Vol. 65, Issue 6) Peer-Reviewed

  Nov-Dec 20201,816 words Article 1790LByline: Hiroyuki. Goto, Kazunari. Sugita, Osamu. Yamamoto Background: A recent clinical trial has shown the efficacy of an anti-programmed death-1 (PD-1) antibody against advanced squamous cell carcinoma (SCC). The...

• The Cancer Immunotherapy Biomarker Testing Landscape.

  Authors:Eric E. Walk, Sophia L. Yohe, Amy Beckman, Andrew Schade, Mary M. Zutter, John Pfeifer, et al.From:Archives of Pathology & Laboratory Medicine (Vol. 144, Issue 6) Peer-Reviewed

  June 202014,425 words Article 2040L* Context.--Cancer immunotherapy provides unprecedented rates of durable clinical benefit to late-stage cancer patients across many tumor types, but there remains a critical need for biomarkers to accurately predict...

• Transdiaphragmatic nephrectomy with synchronous pulmonary and anterior thoracic wall mass metastasectomy in a young male with metastatic renal cell carcinoma; a single-incision approach.

  Authors:Lazaros Lazarou, Marinos Berdempes, Angeliki Peninta, Maria Mitselou, Andreas Skolarikos, and Achilleas LiouliasFrom:Urology Annals (Vol. 13, Issue 2) Peer-Reviewed

  April-June 20211,787 words Article 1580LByline: Lazaros. Lazarou, Marinos. Berdempes, Angeliki. Peninta, Maria. Mitselou, Andreas. Skolarikos, Achilleas. Lioulias Renal cell carcinoma represents approximately 3% of all cancers, with the highest incidence...

• Exploring immunotherapy in colorectal cancer.

  Authors:Junyong Weng, Shanbao Li, Zhonglin Zhu, Qi Liu, Ruoxin Zhang, Yufei Yang, et al.From:Journal of Hematology & Oncology (Vol. 15, Issue 1) Peer-Reviewed

  July 16, 202212,212 words Article 1420LChemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characteristics of the...

• The Relationship Between Checkpoint Inhibitors and the Gut Microbiome and Its Application in Prostate Cancer.

  Authors:Ashray Maniar, Amy E. Moran, and Julie N. GraffFrom:Oncology (Vol. 34, Issue 3) Peer-Reviewed

  Mar. 20204,144 words Article 2010LIndications for checkpoint inhibitors (CPIs) are growing rapidly within the field of oncology; however, they continue to have heterogeneous outcomes in different cancers. Other than mismatch repair deficiency, there are...

• Therapy broadens immune response

  From:Nature (Vol. 513, Issue 7519) Peer-Reviewed

  Sept. 25, 2014139 words Brief article 1510LA drug that activates the immune system against a type of skin cancer does so by promoting new immune responses to cancer, rather than amplifying pre-existing ones. The melanoma drug ipilimumab boosts the activity of...

• Roche splashes $2.4 billion on Foundation Medicine's cancer platform.

  Author:Cormac SheridanFrom:Nature Biotechnology (Vol. 36, Issue 9) Peer-Reviewed

  Oct. 20181,878 words Article 1420LAuthor(s): Cormac Sheridan 1 Author Affiliations: (1) Dublin, Roche has redoubled its commitment to precision oncology by taking full ownership of Foundation Medicine, a pioneer of genomic tumor profiling, in a...

• Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential

  Authors:Koen van de Ven and Jannie BorstFrom:Immunotherapy (Vol. 7, Issue 6) Peer-Reviewed

  July 201510,161 words Report 1820LAuthor(s): Koen van de Ven aff1 , Jannie Borst [*] aff1 Keywords: antibody; cancer; co-inhibition; co-stimulation; cytotoxic T cell; immunotherapy; ipilimumab; nivolumab; TNF receptor family The promise of...

• Time to dissect the autoimmune etiology of cancer antibody immunotherapy.

  Authors:Michael Dougan and Massimo PietropaoloFrom:Journal of Clinical Investigation (Vol. 130, Issue 1) Peer-Reviewed

  Jan. 20208,857 words Article 1430LImmunotherapy has transformed the treatment landscape for a wide range of human cancers. Immune checkpoint inhibitors (ICIs), monoclonal antibodies that block the immune-regulatory "checkpoint" receptors CTLA-4, PD-1, or...

• Predictive Biomarkers for Immunotherapy Response Beyond PD-1/PD-L1.

  Authors:Sourat Darabi, David R. Braxton, Burton L. Eisenberg, and Michael J. DemeureFrom:Oncology (Vol. 34, Issue 8) Peer-Reviewed

  Aug. 20205,286 words Article 1820LAdvances in immuno-oncology over the last several years have led to FDA approvals of novel agents. As our understanding of immune response and its checkpoints has evolved, further advances have been made in treatment for...

• Immune checkpoint inhibitors (Nivolumab)-induced enterocolitis demonstrated on 18Fluorine-fluorodeoxyglucose positron emission tomography-computed tomography.

  Authors:Sharjeel Usmani, Rashid Rasheed, Fahad Marafi, and Fareeda Al KandariFrom:Indian Journal of Nuclear Medicine (Vol. 34, Issue 2) Peer-Reviewed

  April-June 2019875 words Article 1710LByline: Sharjeel. Usmani, Rashid. Rasheed, Fahad. Marafi, Fareeda. Al Kandari Nivolumab, an immune checkpoint inhibitor, is a humanized anti-programmed death-1 monoclonal antibody that is used for the treatment of...

• Disproportionality analysis of acetaminophen-induced hepatic disorders with and without immune checkpoint inhibitors.

  Authors:Tomoyuki Yamada, Ryuji Kato, Yoshio Ijiri, Masami Nishihara, and Masashi NeoFrom:International Journal of Clinical Pharmacy (Vol. 45, Issue 2) Peer-Reviewed

  Apr. 20234,692 words Clinical report 1380LBackground Although acetaminophen is recommended for the treatment of mild-to-moderate cancer pain, acetaminophen-induced hepatic disorders pose an important clinical challenge. Concomitant prescription of immune...

• Diversification of antitumour immunity in a patient with metastatic melanoma treated with ipilimumab and an IDO-silenced dendritic cell vaccine

  Authors:Mouldy Sioud, Marta Nyakas, Stein Saeboe-Larssen, Anne Mobergslien, Steinar Aamdal, and Gunnar KvalheimFrom:Case Reports in MedicinePeer-Reviewed

  Annual 20163,174 words Case study 1360LIndoleamine 2,3-dioxygenase (IDO) expression in dendritic cells (DCs) inhibits T-cell activation and promotes T-cell differentiation into regulatory T-cells. Moreover, IDO expression promotes resistance to...

• Surgical Management of Lymph Node Basin in Sentinel Lymph Node-Positive Melanoma: Why Complete Lymph Node Dissection Remains the Standard of Care

  Authors:Amod A. Sarnaik, Jonathan S. Zager, and Vernon K. SondakFrom:Oncology (Vol. 30, Issue 10) Peer-Reviewed

  Oct. 20161,235 words Article 1750LA positive sentinel lymph node (SLN) is the most important prognostic factor in patients with clinically localized melanoma.[1,2] Complete lymph node dissection (CLND; by definition, lymph node dissection of the...

• Novel therapies in melanoma

  Authors:Benjamin Scheier, Rodabe Amaria, Karl Lewis, and Rene GonzalezFrom:Immunotherapy (Vol. 3, Issue 12) Peer-Reviewed

  Dec. 20116,242 words Report 1440LAuthor(s): Benjamin Scheier 1 , Rodabe Amaria 2 , Karl Lewis 2 , Rene Gonzalez [**] 3 KEYWORDS : BRAF; CTLA-4; ipilimumab; MAPK; MEK; metastatic melanoma; targeted therapy; vemurafenib Current therapies...

• Learning From Our Aging Population: Studying Immune Checkpoint Inhibitors Sheds New Light on the Changing Immune System

  Author:Liz KuneyFrom:American Medical Writers Association Journal (Vol. 34, Issue 1)

  Spring 20194,677 words Article 1990LThe aging of the Baby Boomer generation and the general rise in life expectancy continue to expand the proportion of older adults ([greater than or equal to]65 years of age) across global and US populations. As the...

• Immunotherapies: Exploiting the Immune System for Cancer Treatment

  Authors:Jeffrey Koury, Mariana Lucero, Caleb Cato, Lawrence Chang, Joseph Geiger, Denise Henry, et al.From:Journal of Immunology Research (Vol. 2018) Peer-Reviewed

  Annual 201812,042 words Article 1540LCancer is a condition that has plagued humanity for thousands of years, with the first depictions dating back to ancient Egyptian times. However, not until recent decades have biological therapeutics been developed and...